Phase III Study of Socazolimab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical Cancer

This Phase 3 trial studies whether adding socazolimab (an immunotherapy drug) to standard chemotherapy works better than chemotherapy alone as a first-line treatment for advanced or recurring cervical cancer. **You may be eligible if...** - You are female, age 18–75 - You have cervical cancer confirmed by biopsy (squamous cell, adenocarcinoma, or adenosquamous type) - Your cancer cannot be cured with surgery or radiation alone - You have at least one measurable tumor on CT or MRI scan - You are in reasonably good health (ECOG score 0–1) with a life expectancy of at least 3 months - You have not previously received immunotherapy or anti-angiogenic drugs (like bevacizumab) **You may NOT be eligible if...** - You have a rare type of cervical cancer (small cell, clear cell, sarcoma) - You have had another active cancer in the last 3 years - You have an active autoimmune disease - You have uncontrolled infections or serious organ problems Talk to your doctor to see if this trial is right for you.